Relmada Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
RLMD Nasdaq 2830 www.relmada.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Relmada Therapeutics, Inc.

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 - Jul 15th, 2025 6:00 am
DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors - Jul 9th, 2025 6:00 am
Relmada Therapeutics' Market Cap Drops To US$22m Leaving Insiders With Losses - Jun 28th, 2025 7:50 am
Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology - Jun 17th, 2025 5:00 am
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... - May 13th, 2025 1:09 am
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - May 12th, 2025 2:01 pm
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - May 8th, 2025 5:30 am
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Apr 28th, 2025 11:38 am
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - Apr 27th, 2025 7:00 am
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - Apr 24th, 2025 6:00 am
Relmada Therapeutics To Present NDV-01 Data at AUA2025 - Apr 14th, 2025 5:30 am
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... - Mar 28th, 2025 1:03 am
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - Mar 27th, 2025 2:05 pm
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - Mar 26th, 2025 7:00 am
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. - Mar 25th, 2025 5:30 am
Relmada acquires Tourette’s therapy rights from Asarina - Feb 7th, 2025 4:46 am
Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB - Feb 6th, 2025 5:30 am
US Penny Stocks To Watch In January 2025 - Jan 2nd, 2025 10:06 am
Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 - Dec 9th, 2024 5:30 am
Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile - Dec 5th, 2024 5:36 am